Daiichi sends in posse to keep Ranbaxy plant in line

Daiichi Sankyo isn't taking chances on Ranbaxy Laboratories' ability to keep turning out FDA-compliant drugs. The Japanese drugmaker, which owns the controlling interest in the Indian company, has dispatched two executives to the Punjab facility to keep a close eye on operations there, The Economic Times says. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.